Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 4, 2014, Pages 505-512

  Rinker II, John R ^a,b   Salter, Amber R ^c   Cutter, Gary R ^c  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Multiple sclerosis; Natalizumab; Neurologic symptoms; Questionnaires; Self report; Tremor

Indexed keywords

ALCOHOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; FINGOLIMOD; GABAPENTIN; GLATIRAMER; MEDICAL CANNABIS; NATALIZUMAB; PREGABALIN; PRIMIDONE; SPASMOLYTIC AGENT;

ADULT; AGE; ARTICLE; ATAXIA; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; RATING SCALE; REMISSION; SEX DIFFERENCE; TREATMENT OUTCOME; TREMOR; TREMOR RELATED ACTIVITIES OF DAILY LIVING; VISUAL ANALOG SCALE;

EID: 84902546068     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2014.04.001     Document Type: Article

References (31)

1. S.H. Alusi, J. Worthington, S. Glickman, and P.G. Bain A study of tremor in multiple sclerosis Brain 124 2001 720 730
2. P.G. Bain, and L.J. Findley Assessing tremor severity 1st ed. 1993 Smith-Gordon and Company Ltd. London p. 5 24
3. L.J. Balcer, S.L. Galetta, C.H. Polman, E. Eggenberger, P.A. Calabresi, and A. Zhang et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS J Neurol Sci 318 2012 119 124
4. C.B. Bozek, L.F. Kastrukoff, J.M. Wright, T.L. Perry, and T.A. Larsen A controlled trial of isoniazid therapy for action tremor in multiple sclerosis J Neurol 234 1987 36 39
5. Consortium of Multiple Sclerosis Centers. NARCOMS multiple sclerosis registry (on-line). http://www.narcoms.org/ [accessed 8.12.13].
6. P. Fox, P.G. Bain, S. Glickman, C. Carroll, and J. Zajicek The effect of cannabis on tremor in patients with multiple sclerosis Neurology 62 2004 1105 1109
7. M.G. Grasso, S. Lubich, L. Guidi, D. Rinnenburger, and S. Paolucci Cerebellar deficit and respiratory impairment: a strong association in multiple sclerosis? Acta Neurol Scand 101 2000 98 103
8. M. Hallett, J.W. Lindsey, B.D. Adelstein, and P.O. Riley Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis Neurology 35 1985 1374 1377
9. H.P. Hartung, R. Gonsette, N. Koenig, H. Kwiecinski, A. Guseo, and S.P. Morrissey et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial Lancet 360 2002 2018 2025
10. C. Hirst, G. Ingram, O. Pearson, T. Pickersgill, N. Scolding, and N. Robertson Contribution of relapses to disability in multiple sclerosis J Neurol 255 2008 280 287
11. P. Iaffaldano, R.G. Viterbo, D. Paolicelli, G. Lucchese, E. Portaccio, and B. Goretti et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: A prospective, open-label, two years observational study PLoS One 7 2012 e35843
12. IFN β Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 1993 655 661
13. L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.M. Herndon, J.R. Richert, and A.M. Salazar et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Ann Neurol 39 1996 285 294
14. K.P. Johnson, B.R. Brooks, J.A. Cohen, C.C. Ford, J. Goldstein, and R.P. Lisak et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 45 1995 1268 1276
15. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfield, and P. Calabresi et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
16. M. Koch, J. Mostert, D. Heersema, and J. De Keyser Tremor in multiple sclerosis J Neurol 254 2007 133 145
17. C. Lang, C. Reiss, and M. Maeurer Natalizumab may improve cognition and mood in multiple sclerosis Eur Neurol 67 2012 162 166
18. E.D. Louis, and J.J. Ferreira How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor Mov Disord 25 2010 534 541
19. F.D. Lublin, M. Baier, and G. Cutter Effect of relapses on development of residual deficit in multiple sclerosis Neurology 61 2003 1528 1532
20. R.A. Marrie, and M. Goldman Validation of the NARCOMS registry: tremor and coordination scale Int J MS Care 13 2011 114 120
21. J.T. Phillips, G. Giovannoni, F.D. Lublin, P.W. O'Connor, E. Willoughby, and W. Aschenback et al. Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis Mult Scler 17 2011 970 979
22. S. Pittock, R. McClelland, W. Mayr, M. Rodriguez, and J.Y. Matsumoto Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population Mov Disord 19 2004 1482 1485
23. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller et al. A randomized placebo-controlled trial of natalizumab for relapsing-remitting multiple sclerosis N Engl J Med 354 2006 899 910
24. A. Prat, and J. Antel Pathogenesis of multiple sclerosis Curr Opin Neurol 18 2005 225 230
25. PRISMS Study Group; Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis; Lancet; 1998;352;1498-1504.
26. P. Striano, A. Coppola, G. Vacca, F. Zara, V. Brescia Morra, and G. Orefice et al. Levetiracetam for cerebellar tremor in multiple sclerosis. an open-label pilot tolerability and efficacy study J Neurol 253 2006 762 766
27. D.T. Wade, P. Makela, P. Robson, H. House, and C. Bateman Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients Mult Scler 10 2004 434 441
28. B.G. Weinshenker, G.P. Rice, J.H. Noseworthy, W. Carriere, J. Baskerville, and G.C. Ebers The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome Brain 114 1991 1045 1056
29. N. Weiss, R.B. North, S. Ohara, and F.A. Lenz Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report J Neurosurg 99 2003 768 771
30. T.A. Yednock, C. Cannon, L.C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin Nature 356 1992 63 66
31. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, and A. Nunn et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomized placebo-controlled trial Lancet 362 2003 1517 1526